AGIO Agios Pharmaceuticals Inc.

Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. ET to report its second quarter 2020 financial results and other business highlights.

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 2955575. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.

About Agios

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at

Contacts

Investors:

Holly Manning, 617-844-6630

Director, Investor Relations

Media:

Jessica Rennekamp, 857-209-3286

Associate Director, Corporate Communications

EN
16/07/2020

Underlying

AGIOAgios Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agios Pharmaceuticals Inc.

 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Reports Third Quarter 2025 Financial Results and Provides Busine...

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update $12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026$1.3 billion dollars in cash, cash equivalents and marketable securiti...

October 30, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults...

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anemia associated wi...

October 17, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios to Host Third Quarter 2025 Financial Results Conference Call and...

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the comp...

October 16, 2025 1 EN
Free Trial
AGIO Agios Pharmaceu...

Agios Pharmaceuticals Inc: 1 director

A director at Agios Pharmaceuticals Inc sold 8,546 shares at 36.870USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

AGIO AGIOS PHARMACEUTICALS INC.
09/10/25 September 10, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat...

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat)...

September 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch